Glenmark 3.0 targets 70% branded revenue by 2030

A pivot designed to move beyond generics

Glenmark Pharmaceuticals is recalibrating its strategy to become a global, innovation-led drugmaker, reflecting a broader shift underway across parts of Indian pharma. Chairman and Managing Director Glenn Saldanha has described the transition as a multi-year effort that needs patience, capital, and a tolerance for failures. The company’s “Glenmark 3.0” roadmap places heavier weight on novel drug development, selective partnerships, and branded commercial execution, while keeping generics as an ongoing growth engine.

In interviews and public forums, Saldanha has said the next decade is focused on building an innovation-led portfolio “brick by brick,” with setbacks expected along the way. The company’s approach combines licensing, co-development tie-ups, and Glenmark’s own commercialization, especially in emerging markets.

The AbbVie deal that validated Glenmark’s discovery bet

A key inflection point came in 2025, when Glenmark licensed its trispecific antibody therapy ISB-2001 to AbbVie. The agreement included an upfront payment of $100 million and potential milestones of $1,200 million-plus. The company positioned the transaction as evidence that drug discovery originating from India-linked platforms can compete globally.

Glenmark’s innovation engine has been built through Ichnos Glenmark Innovation (IGI), which is linked to the company’s US-based biotech arm, Ichnos Sciences, and Glenmark Pharmaceuticals Ltd. Saldanha has framed ISB-2001 as a product of a long, sustained effort to move up the value chain, after the global generics model increasingly became a scale-and-cost contest.

Glenmark 3.0: what the plan says

Saldanha has described “Glenmark 3.0” as a plan to make the portfolio more innovation-driven over the next 4-5 years, while maintaining a large commercial footprint. By 2030, the company has said it wants 70% of revenue to come from branded products, up from a stated base of 60%.

At an investor day in Mumbai, Saldanha said Glenmark sees itself “2030 and onwards” as a leading global innovation-driven company with leadership in three therapeutic areas: dermatology, respiratory, and oncology. The branded mix matters in Glenmark’s narrative because it is intended to reduce vulnerability to generic price erosion, particularly in markets such as the US.

What Glenmark says about its current revenue mix

Glenmark has provided more than one snapshot of its revenue composition in the material provided. In one statement, Saldanha said last year, 60% of revenue came from branded products. In another, he said almost 65% of revenues are coming from branded business, describing it as a stabilizer against pricing pressures.

The company has also indicated an operational base built across its core business, citing India performance and global presence across more than 80 countries. A separate description referred to Glenmark as a $1,600 million organisation.

Revenue guidance and near-term growth commentary

Saldanha has said Glenmark expects to record ₹135,000 million to ₹140,000 million in revenue in the current year, and reach about ₹155,000 million next year. He also referred to growth of about 12%-15% CAGR in that context.

These figures are positioned as the financial foundation that supports increased investment in innovation and branded scaling. Glenmark has also said it intends to do this in a fiscally disciplined way, with attention to margins and return ratios.

Portfolio choices: why Glenmark sold its API business

Responding to analyst questions after the sale of Glenmark Life Sciences (GLS), its active pharmaceutical ingredient (API) business, Saldanha said the divestment reflected changing dynamics in generics. He said the company did not see the need to retain the API business within the portfolio and that the sale allowed Glenmark to re-channel energies into becoming a branded company.

He also described the move as part of broader portfolio rationalisation, while insisting the company would not “give up” on scale. The message is that the company wants to keep building commercial breadth while reallocating management focus and capital toward branded and innovative assets.

Partnerships and in-licensing: building the pipeline and portfolio

Alongside internal R&D, Glenmark has highlighted partnerships to access innovative therapies across geographies. The company announced tie-ups with Jiangsu Alphamab Biopharmaceuticals and 3D Medicines for KN035 (Envafolimab) for multiple geographies. It also partnered with Pfizer to launch Abrocitinib for atopic dermatitis in India under the brand name Jabryus.

Saldanha has described the forward model as a mix of “more molecules” across early research and partnering as programs mature. The stated intent is to combine discovery progress with deal-making and commercial execution, instead of relying on any single lever.

R&D and profitability targets mentioned earlier

In a strategic blueprint described previously, Glenmark said it planned to transition from a pure generics-driven company to three pillars: global generics, specialty products, and innovative products. It also said it hoped to generate 30% of revenue by 2025 from specialty and innovative products alone.

To invest in specialty and innovation, the company said R&D expenses would stay at roughly 11%-12% of revenues. In the same context, Saldanha said he expected profitability margins to improve from 22% to 25% by 2025.

Key figures and targets at a glance

Why this matters for Indian pharma investors

Glenmark’s plan underscores a larger investor question: whether Indian drugmakers can build durable value beyond generics, despite higher risk, long timelines, and frequent clinical setbacks. The company is explicitly placing innovation, multi-specific oncology programs, and branded scaling at the center of its next phase.

At the same time, management is describing a blended model rather than an abrupt switch, keeping generics as a growth driver while pushing branded products in priority therapies and using licensing to monetize discovery. The clearest near-term markers are execution against branded mix targets, the cadence of partnerships and launches, and progress within IGI-led innovation programs.

Conclusion

Glenmark’s “3.0” narrative ties together a long-running shift toward innovation, a higher branded revenue mix, and a partnership-heavy path to building global relevance. The 2025 AbbVie ISB-2001 transaction remains the most visible validation point for its discovery engine. Over the next few years, the company’s stated milestones include expanding branded contribution toward the 2030 goal and continuing to build its pipeline and commercial footprint across key markets and therapy areas.